NANS 2020: Boston Scientific Expects Neuromodulation Business Rebound In 2020
At NANS, Boston Scientific presented results of the COMBO study, announced a partnership with IBM Research on digital health, and reported strong US growth in its deep brain stimulation business. Boston's C suite sees rebound for lagging neuromodulation business in 2020.
You may also be interested in...
Among the company's many milestones in the first quarter, the FDA approved its Therasphere radiation seed device, a major building block of the company's interventional oncology business.
SENZA PDN showed Nevro's HF10 spinal cord stimulation therapy provided sustained relief to patients with painful diabetic neuropathy. Results of a separate trial showed HF10 improved outcomes in patients with non-surgical refractory back pain.
Boston Scientific’s WaveWriter Alpha spinal cord stimulation devices feature the proprietary FAST software for rapid, paresthesia-free pain relief of chronic pain.